Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

¹ðÁÖÈý½ðBC006µ¥¿¹×¢ÉäÒºÐÂÔö˳Ӧ֢»ñÅúÁÙ´² | 1·ÖÖÓÒ©ÎÅËÙÀÀ

2025-05-05
|
»á¼ûÁ¿£º

0506.jpgÒ½ÏßÒ©ÎÅ

1. 5ÔÂ5ÈÕ£¬£¬£¬£¬£¬¹ðÁÖÈý½ðͨ¸æ£¬£¬£¬£¬£¬¿ËÈÕ£¬£¬£¬£¬£¬¹«Ë¾¿Ø¹ÉË﹫˾±¦´¬ÉúÎïÒ½Ò©¿Æ¼¼ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄBC006µ¥¿¹×¢ÉäÒºµÄÁÙ´²ÊÔÑéÅú¼þ£¬£¬£¬£¬£¬Ô޳ɸÃÒ©Æ·¿ªÕ¹ÓÃÓÚÌØ·¢ÐÔ·ÎÏËά»¯Ë³Ó¦Ö¢µÄÁÙ´²ÊÔÑé¡£¡£¡£

2. 4ÔÂ29ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬ÉϺ£¸´ÐÇÒ½Ò©¹¤ÒµÉú³¤ÓÐÏÞ¹«Ë¾É걨µÄFCN-159ƬÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ£¬£¬£¬£¬£¬Õë¶Ô˳Ӧ֢Ϊ¶ùͯÀʸñººË¹×é֯ϸ°ûÔöÉúÖ¢£¨LCH£©¡£¡£¡£

3. ¿ËÈÕ£¬£¬£¬£¬£¬ÓÉÖйú¿ÆÑ§ÔºÉϺ£Ò©ÎïÑо¿ËùºÍÑĮ̀ÐÂÒ©´´Ôìɽ¶«Ê¡ÊµÑéÊÒÁªºÏÉ걨µÄ»¯Ò©1ÀàÐÂÒ©X-L177½ºÄÒ£¬£¬£¬£¬£¬ÀֳɻñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö½ÒÏþµÄÁÙ´²ÊÔÑé֪ͨÊ飬£¬£¬£¬£¬»ñ×¼¿ªÕ¹ÖÎÁÆËèϵ¶ñÐÔÖ×ÁöµÄIÆÚÁÙ´²ÊÔÑé¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. Åµ»ªÍýÏëÒÔ8ÒÚÃÀÔªÔ¤¸¶¿îÊÕ¹ºÎ»ÓÚÊ¥µØÑǸçµÄÉúÎï¿Æ¼¼¹«Ë¾Regulus Therapeutics£¬£¬£¬£¬£¬¸Ã¹«Ë¾×¨×¢ÓÚmicroRNAÒ©ÎïµÄÑз¢¡£¡£¡£´Ë´ÎÊÕ¹ºµÄ½¹µã×ʲúÊÇfarabursen£¬£¬£¬£¬£¬ÕâÊÇÒ»ÖÖÕë¶ÔÓëÉö²¡Ïà¹ØµÄmiR-17µÄºòѡҩÎ£¬£¬£¬£¬¸ÕÍê³ÉÕë¶Ô¶àÄÒÉö²¡»¼ÕßµÄ1bÆÚÁÙ´²ÊÔÑé¡£¡£¡£

2. ¿ËÈÕ£¬£¬£¬£¬£¬ÖÇкÆÕý£¨ÉϺ££©Ò½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼Íê³É½ü 2 ÒÚÔªÈËÃñ±ÒÈÚ×Ê£¬£¬£¬£¬£¬±¾ÂÖÈÚ×ÊÓÉÒÚÔª A ÂÖÈÚ×ʺÍÀϹɶ«Ôö×浀 Pre-A+ ÂÖÅäºÏ×é³É¡£¡£¡£ÐÂΟåÖ¸³ö£¬£¬£¬£¬£¬±¾ÂÖ×ʽð½«ÖصãÍÆ½øº£ÄÚÊ׸öÒìÌåͨÓÃÐÍÔÙÉúÒȵº¹ÜÏßÁÙ´² I/II ÆÚÊÔÑ飬£¬£¬£¬£¬¼ÓËÙÍØÕ¹ÑÇÖÞÕ½ÂԽṹ£¬£¬£¬£¬£¬¿ªÍØÌÇÄò²¡ºÍ¸Î²¡ÖÎÁƵÄйÜÏß¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 4ÔÂ25ÈÕ£¬£¬£¬£¬£¬É½¶«´óѧÆë³ҽԺÕųÎ/ÕÅÃͽÌÊÚÍŶÓÔÚ Signal Transduction and Targeted Therapy ÔÓÖ¾ÉϽÒÏþÁËÌâΪ¡¸STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation¡¹µÄÑо¿ÂÛÎÄ¡£¡£¡£¸ÃÑо¿Ê×´ÎÃ÷È·ÁËÒ»ÖÖеÄ×ÔÊÉÒÀÀµÐÔÌúéæÃü»úÖÆ£¬£¬£¬£¬£¬ÆÊÎöÁËȱÑõ»òȱѪÔÙ¹à×¢ÓÕµ¼µÄ STING ×ÔÊɻᵼÖ GPX4 ½µ½â£¬£¬£¬£¬£¬ÎªÈ±ÑªÐÔÐÄÔಡµÄÖÎÁÆÌṩÁËеIJßÂԺ͸ÉÔ¤°Ðµã¡£¡£¡£

[1]Wang, X., Chen, T., Chen, S. et al. STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation. Sig Transduct Target Ther 10, 136 (2025). https://doi.org/10.1038/s41392-025-02216-9

Ïà¹ØÐÂÎÅ
¡¾ÃÀ¸ß÷ÖúÁ¦¡¿°Ù°ÂÌ©µ¥¿¹×¢ÉäÒºBAT1308»ñµÃ¡¶ÁÙ´²ÊÔÑé֪ͨÊé¡·
2020-06-04
2020Äê5ÔÂ27ÈÕ£¬£¬£¬£¬£¬°Ù°ÂÌ©ÉúÎïÖÆÒ©¹É·ÝÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°°Ù°ÂÌ©¡±£©Ðû²¼£¬£¬£¬£¬£¬¹«Ë¾ÓÚ2020Äê05ÔÂ26ÈÕÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¹ØÓÚ¹«Ë¾ÔÚÑÐÒ©Æ·BAT 1308×¢ÉäÒºµÄ¡¶ÁÙ´²ÊÔÑé֪ͨÊé¡·¡£¡£¡£
ÀñÀ´ÒÀÆæÖéµ¥¿¹×¢ÉäÒºÔÚ»ª»ñÅúÐÂ˳Ӧ֢ÖÎÁÆÇ¿Ö±ÐÔ¼¹ÖùÑר­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2022-08-02
8ÔÂ1ÈÕ£¬£¬£¬£¬£¬ÀñÀ´¹«Ë¾Ðû²¼£¬£¬£¬£¬£¬ÆäÒÀÆæÖéµ¥¿¹×¢ÉäÒºÕýʽ»ñµÃÖйú¹ú¼ÒÒ©¼à¾Ö£¨NMPA£©Åú×¼£¬£¬£¬£¬£¬ÓÃÓÚͨÀýÖÎÁÆÁÆÐ§Ç·¼ÑµÄÔ˶¯ÐÔǿֱÐÔ¼¹ÖùÑ׳ÉÈË»¼Õß¡£¡£¡£ÒÀÆæÖéµ¥¿¹×¢ÉäÒºÊÇÒ»¿î°ÐÏòIL-17Aµ¥¿¹¡£¡£¡£´Ë´Î»ñÅúÊÇÒÀÆæÖéµ¥¿¹×¢ÉäÒºÔÚÖйú»ñÅúµÄµÚ¶þÏî˳Ӧ֢¡£¡£¡£
Ó¢ÎùÖÇÄÜÌØ·¢ÐÔ·ÎÏËά»¯ÐÂÒ©»ñFDA¹Â¶ùÒ©×ʸñØ­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-02-03
2ÔÂ3ÈÕ£¬£¬£¬£¬£¬ÃÀ¸ß÷ÏàÖú¿Í»§Ó¢ÎùÖÇÄÜ£¨Insilico Medicine£©Ðû²¼£¬£¬£¬£¬£¬¸Ã¹«Ë¾Ê׸öȫлúÖÆºòѡҩÎïINS018_055»ñµÃÃÀ¹úFDAÊÚÓèµÄ¹Â¶ùÒ©×ʸñ£¬£¬£¬£¬£¬Ä⿪·¢ÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯¡£¡£¡£INS018_055ÊÇÒ»¿î¾ßÓÐÈ«ÇòÊ×´´Ç±Á¦µÄС·Ö×ÓÒÖÖÆ¼Á¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿